These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9226562)

  • 21. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population.
    LaGuardia KD
    Obstet Gynecol; 2006 Dec; 108(6):1553-4. PubMed ID: 17138794
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
    Görög S
    Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple, rapid and sensitive UFLC-MS/MS method for the quantification of oral contraceptive norgestrel in human plasma and its pharmacokinetic applications.
    Batta N; Pigili RK; Pallapothu LM; Yejella RP
    Drug Res (Stuttg); 2014 Sep; 64(9):462-9. PubMed ID: 24310360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of an oral contraceptive (ethinylestradiol/D-norgestrel) on growth hormone and insulin secretion].
    Hausmann L; Goebel KM; Zehner J
    Schweiz Med Wochenschr; 1976 Oct; 106(43):1470-4. PubMed ID: 1013665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical and biochemical effects of two combination oral contraceptive agents.
    Sapire KE; Berger GM; Maritz JS
    S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [What does the micropill bring?].
    Mall-Haefeli M
    Ther Umsch; 1986 May; 43(5):365-71. PubMed ID: 2941889
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The synthetic progestin norgestrel acts to increase LIF levels in the rd10 mouse model of retinitis pigmentosa.
    Byrne AM; Roche SL; Ruiz-Lopez AM; Jackson AC; Cotter TG
    Mol Vis; 2016; 22():264-74. PubMed ID: 27081297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some observations on the changes in capillary resistance in oral contraceptive users.
    Zaki K; Younis MN; Razek SA; Mekkawi TE; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):145-51. PubMed ID: 12256025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimation of impurity profiles in drugs and related materials. Part 11--The role of chromatographic and spectroscopic methods in the estimation of side-reactions in drug syntheses.
    Görög S; Balogh G; Csehi A; Csizér E; Gazdag M; Halmos Z; Hegedüs B; Herényi B; Horváth P; Laukó A
    J Pharm Biomed Anal; 1993; 11(11-12):1219-26. PubMed ID: 8123737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cilest--a combined OC.
    Drug Ther Bull; 1991 Dec; 29(26):103-4. PubMed ID: 1790761
    [No Abstract]   [Full Text] [Related]  

  • 39. Ovarian function during treatment with high ratio levonorgestrel/ethinyl estradiol as oral contraceptives.
    Johansson ED; Elamsson K; Elmestedt U
    Gynecol Obstet Invest; 1982; 14(2):97-105. PubMed ID: 6811379
    [No Abstract]   [Full Text] [Related]  

  • 40. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.